Published in Neuroimage on June 30, 2009
Approaches to quantify radioligands that wash out slowly from target organs. Eur J Nucl Med Mol Imaging (2010) 1.52
Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28. PLoS One (2011) 1.31
Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med (2009) 1.31
Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur J Nucl Med Mol Imaging (2009) 0.96
Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab (2012) 0.93
Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography. Eur J Nucl Med Mol Imaging (2010) 0.92
Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology (Berl) (2011) 0.88
Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. Alcohol Clin Exp Res (2012) 0.86
Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase. Bioorg Med Chem (2013) 0.84
Retest imaging of [11C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. Neuroimage (2013) 0.83
Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol (2012) 0.82
Endocannabinoid signaling in the etiology and treatment of major depressive illness. Curr Pharm Des (2014) 0.80
In vitro and in vivo evaluation of (11)C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. Neuroimage (2013) 0.80
Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model. Eur J Nucl Med Mol Imaging (2012) 0.80
The impact of ADHD persistence, recent cannabis use, and age of regular cannabis use onset on subcortical volume and cortical thickness in young adults. Drug Alcohol Depend (2016) 0.80
Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [¹¹C]MePPEP. Neuroimage (2014) 0.79
Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. J Cereb Blood Flow Metab (2015) 0.79
Preclinical evaluation and quantification of [¹⁸F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain. Eur J Nucl Med Mol Imaging (2012) 0.78
Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults. Neuroimage Clin (2015) 0.78
Neuroimaging in Huntington's disease. World J Radiol (2014) 0.78
[¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease. Neurochem Int (2011) 0.78
Improved models for plasma radiometabolite correction and their impact on kinetic quantification in PET studies. J Cereb Blood Flow Metab (2015) 0.78
N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors. J Med Chem (2011) 0.77
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. Neuropharmacology (2015) 0.77
Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism. Eur J Nucl Med Mol Imaging (2010) 0.77
Impact of cannabis use on prefrontal and parietal cortex gyrification and surface area in adolescents and emerging adults. Dev Cogn Neurosci (2015) 0.76
Guidelines to PET measurements of the target occupancy in the brain for drug development. Eur J Nucl Med Mol Imaging (2016) 0.75
Molecular Imaging Markers to Track Huntington's Disease Pathology. Front Neurol (2017) 0.75
18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study. EJNMMI Res (2013) 0.75
Characterization of fast-decaying PET radiotracers solely through LC-MS/MS of constituent radioactive and carrier isotopologues. EJNMMI Res (2013) 0.75
In vivo SPECT and ex vivo autoradiographic brain imaging of the novel selective CB1 receptor antagonist radioligand [125I]SD7015 in CB1 knock-out and wildtype mouse. Brain Res Bull (2013) 0.75
Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage (2002) 49.90
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience (1997) 2.56
Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci (1994) 2.31
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol (1996) 1.78
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A (2007) 1.73
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry (2008) 1.64
Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumors with PET. J Cereb Blood Flow Metab (1986) 1.62
PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett (2006) 1.56
Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol (1997) 1.36
The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. Neuropsychopharmacology (2007) 1.34
11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med (2006) 1.32
Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. J Med Chem (2008) 1.30
End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov (2008) 1.19
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem (1998) 1.16
Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage (2007) 1.12
Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes (Lond) (2006) 1.01
Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament. Arch Gen Psychiatry (2009) 1.01
Kinetics of binding to opiate receptors in vivo predicted from in vitro parameters. Brain Res (1984) 1.00
Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage (2008) 0.99
Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab (2003) 3.77
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry (2008) 3.51
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab (2002) 2.58
Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage (2007) 2.50
Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49
PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med (2006) 2.20
Synthesis and evaluation in monkey of two sensitive 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J Med Chem (2007) 2.11
Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med (2010) 2.00
Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage (2007) 1.91
Fast and high-yield microreactor syntheses of ortho-substituted [(18)F]fluoroarenes from reactions of [(18)F]fluoride ion with diaryliodonium salts. J Org Chem (2010) 1.91
Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med (2005) 1.89
Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv (2004) 1.89
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med (2007) 1.81
Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry (2003) 1.77
Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science (2008) 1.77
Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp (2004) 1.76
Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res (2003) 1.75
Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry (2002) 1.75
Increased midbrain gray matter in Tourette's syndrome. Ann Neurol (2006) 1.69
P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med (2010) 1.62
A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab (2012) 1.59
Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging (2008) 1.58
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain (2013) 1.57
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol (2008) 1.57
PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett (2006) 1.56
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging (2008) 1.55
Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry (2014) 1.54
P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med (2008) 1.53
Approaches to quantify radioligands that wash out slowly from target organs. Eur J Nucl Med Mol Imaging (2010) 1.52
Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry (2009) 1.47
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) (2002) 1.46
Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology (2009) 1.45
Syntheses of 11C- and 18F-labeled carboxylic esters within a hydrodynamically-driven micro-reactor. Lab Chip (2004) 1.44
Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry (2006) 1.44
Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem (2008) 1.43
Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain (2006) 1.43
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther (2002) 1.43
Image-derived input function for brain PET studies: many challenges and few opportunities. J Cereb Blood Flow Metab (2011) 1.42
The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res (2005) 1.42
Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci (2003) 1.41
Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry (2005) 1.40
Application of calibrated image-derived input function to a clinical protocol. Nucl Med Commun (2014) 1.38
11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med (2008) 1.37
Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med (2008) 1.37